Pfizer forecasts $54 billion in revenue in 2022 from sales of Covid vaccines and antiviral drugs

Pfizer is the leading Covid vaccine maker in the US and recently began rolling out what many believe is the most effective antiviral drug available to treat the virus.

The implementation of both has resulted in significant financial returns for the New York City-based company and the prospect of increased distribution of Paxlovid, the potential deployment of a vaccine tailored to Omicron and More booster shots in the future will result in an even more cash flow.

On Tuesday, the company revealed fourth-quarter earnings and revenue projections for 2022. The company is estimated to post sales of up to $102 billion next year, which would be a new record.

More than half of that income will be from the two Covid products, with vaccines expected to bring in $32 billion in revenue and Paxlovid expected to make $22 billion.

Pfizer’s COVID-19 vaccine (pictured) is the most popular vaccine in the US, and sales of the vaccine doubled the company’s fourth-quarter revenue in 2021 compared to 2020. The company expects an additional $32 billion in vaccine sales by 2022

Pfizer Paxlovid’s new oral COVID-19 treatment (pictured) is expected to bring in $22 billion in revenue for the company this year

The Pfizer COVID-19 vaccine is the most commonly used vaccine in the US and many other countries around the world.

According to official data from the US Centers for Disease Control and Prevention (CDC), the shot has been used 319 million times – more than half of the 540 million vaccines used nationwide.

This includes nearly 50 million Pfizer booster injections to be performed.

The company doubled its sales in the fourth quarter of this year from last year, to $23.84 billion in the last three months of last year.

More than half of the revenue, US$12.5 billion, comes from Covid vaccines.

This revenue stream will remain intact for years to come, maybe even the next decade, if Pfizer gets its way.

According to the report, the company plans to launch a specific vaccine of the Omicron variant at some point this spring, increasing protection against the already resistant strain of the virus. appeared in the world last month.

However, by the time footage appeared, the variant might have sold out.

Pfizer CEO Albert Bourla (pictured), says a Covid vaccine may be needed within the next decade to control the pandemic

Covid cases in the US are plummeting, down 43% over the past week, with 17 states recording a daily case rate drop of 70% or more in the past 14 days.

Pfizer expects Covid to last longer than just the proliferation of Omicron and Albert Bourla, the CEO of Pfizer who is a proponent of repeating the Covid boosters.

Last month, he told CNBC’s The Squawk Box that the virus is likely to emerge within the next decade, but regular shooting can help keep it under control.

“We will have a completely normal life, with just injections once a year,” he said.

The company has also been in hot water for allegedly using its power as the world’s top vaccine supplier to take advantage of developing nations.

A Public Citizen report from October found the company worked hard to silence governments, limit countries’ access to vaccine donations, force governments to file lawsuits. lawsuits they could face for violating intellectual property laws and confiscating public assets in the event of missed payments such as offshore bank accounts.

The People’s Vaccine Alliance also reported that Pfizer, BioNTech – their main partner in making the shot – and Moderna – the second most popular vaccine maker – made more than a combined profit. $1,000 per second last year.

Paxlovid, which received an emergency use authorization from the Food and Drug Administration (FDA) in December, opens up another source of Covid-related revenue from the company.

Bourla said the company plans to sell the drug to governments around the world for $700 a course, Bourla said during an earnings press conference Tuesday.

He also added that the company can produce up to 120 million packs of the drug if needed and that it is currently in talks with more than 100 countries to discuss the purchase.

This makes the estimated $22 billion in revenue a potential underestimation if the company can maximize its potential revenue this year.

Source: | This article originally belonged to Dailymail.co.uk